Titre :
  • Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner.
Auteur : Cardoso, Fatima ; Durbecq, Virginie ; Laes, Jean-François ; Badran, Bassam ; Lagneaux, Laurence ; Bex, Françoise ; Desmedt, Christine ; Willard, Karen ; Ross, Jeffrey S. ; Burny, Arsène ; Piccart-Gebhart, Martine ; Sotiriou, Christos
Informations sur la publication : Molecular cancer therapeutics, 5, 12, (page 3042-3051)
Statut de publication : Publié, 2006-12
Sujet CREF : Cancérologie
Médecine pathologie humaine
Sciences bio-médicales et agricoles
Mots-clés MeSH : Antibodies, Monoclonal -- administration & dosage
Antibodies, Monoclonal -- pharmacology
Antineoplastic Combined Chemotherapy Protocols -- pharmacology
Apoptosis -- drug effects
Boronic Acids -- administration & dosage
Boronic Acids -- pharmacology
Breast Neoplasms -- drug therapy
Breast Neoplasms -- enzymology
Breast Neoplasms -- metabolism
Breast Neoplasms -- pathology
Cell Line, Tumor
Cell Nucleus -- metabolism
Cyclin-Dependent Kinase Inhibitor p27 -- metabolism
Drug Resistance, Neoplasm
Drug Synergism
Humans
NF-kappa B -- biosynthesis
NF-kappa B -- metabolism
Pyrazines -- administration & dosage
Pyrazines -- pharmacology
Receptor, erbB-2 -- biosynthesis
Note : Journal Article
Research Support, Non-U.S. Gov't
Langue :
  • Anglais
Identificateurs : urn:issn:1535-7163 
info:doi/10.1158/1535-7163.MCT-06-0104
info:pii/1535-7163.MCT-06-0104
info:pmid/17148762